Anti-transglutaminase 2 antibodies
AssigneeLifearc
InventorsTim Johnson, Phil Watson, David Matthews, Alex Brown
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
Claims12
An antibody or an antigen-binding fragment thereof that binds human transglutaminase type 2 (TG2), wherein the antibody or antigen-binding fragment thereof comprises the amino acid sequences set forth in SEQ ID NO:
- 7 (LCDR1;
- KASQDINSYLT), SEQ ID NO:
- 13 (LCDR2;
- LTNRLMD), SEQ ID NO:
- 14 (LCDR3;
- LQYVDFPYT), SEQ ID NO:
- 10 (HCDR1;
- SSAMS), SEQ ID NO:
- 15 (HCDR2;
- TISSGGRSTYYPDSVKG) and SEQ ID NO:
- 16 (HCDR3;
- LISPY).
Dependencies are inferred from the claim text.